Key Takeaways
- Revenue surges 31% YoY, but mix shift bites: Standalone revenue grew 31% YoY on strong CPVC volumes, yet gross margins compressed to ~31% from 32.6% as the lower-margin CPVC product took a larger share of the mix.
- Egypt is the margin and growth unlock: The Egypt plant, with electricity at one-fifth of India's cost and duty-free access to ~130 countries, targets ₹250–₹300 crores revenue over 3 years at contribution margins 400–500 bps higher than India.
- Bold growth targets set: Management is targeting more than 40% revenue growth in FY27 and a 35% CAGR from FY26 to FY29, underpinned by capacity expansion at Palghar and the Egypt ramp-up.
- Margins have reset, recovery path is laid: EBITDA margins have compressed from 23% to 15% as CPVC scaled from 7% to 17% contribution; management sees 15%–17% as maintainable in India, with Egypt adding a higher-margin layer over time.
- What to watch next quarter: The commercial production start at Egypt (targeted September), the ramp-up of calcium zinc lines from April, and any quantification of pharma revenue, which management declined to provide.
Growth Engine: Egypt Plant
The Egypt facility is the single most consequential initiative for both revenue scale and margin recovery. It manufactures lead-based commodities (lead stabilizers, metallic stearates) and CPVC compounds, with construction completing by end of May, pre-commissioning in June, and commercial production targeted for 1st September, though the exchange filing conservatively points to December for 100% plant running.
- Cost advantage is structural: Electricity in Egypt costs ₹2.9–₹3 per unit versus ₹14.5–₹15 in Maharashtra, pushing contribution margins on lead products to 22%–23% compared to 18% in India.
- Trade access is the hidden multiplier: Egypt holds Multi Free Trade Agreements covering ~130 countries, enabling duty-free imports for customers. Freight to Uzbekistan from Egypt runs ~$450–$500 per container versus $5,500–$6,000 from India, opening markets that were logistically unviable.
- Revenue ambition: Management targets ₹250–₹300 crores from Egypt over 3 years, roughly 50% of the ₹600 crore potential, with initial EBITDA margins of 12%–13% on lead products rising to 15%–16% after the first 2–3 years.
- Lead-risk hedge is built in: If regulations shift against lead, the same machines can switch to calcium zinc production after cleaning, so the asset is not stranded.
Krishna Rana: "Egypt holds around Multi Free Trade Agreements (FTA)... almost 130 countries can import from Egypt duty-free."
India Capacity & Product Mix
The Palghar expansion adds 60,000 MT, expected to be optimally utilised by March/April, taking total India revenue potential to ~₹1,400 crores (₹700–₹750 crores from PVC, ~₹600 crores from CPVC) over three to four years.
- CPVC is the growth driver but the margin diluter: CPVC grew exponentially even as the PVC industry contracted 10%–12% on falling prices. Its contribution margin has improved from 7% last year to 12% in H1 and 17% in Q3, but it still sits below the company's legacy margins because raw material costs are not yet optimised.
- Business model is shifting toward additives: The company now supplies additives rather than complete compounds, letting large customers buy CPVC resin directly and control 75%–80% of formulation themselves. Compounds are still manufactured for smaller customers who lack blending capability.
- Powder capacity utilisation is climbing: Previously at 10%, now at 20%–30%, driven by technology advancement that is converting pipe manufacturers to fittings, a higher-value application. Unit 1 flakes capacity is already at 95%.
- Calcium zinc lines corrected: An automation issue that had constrained calcium zinc production was fixed in February, with full-scale commercial production expected from April.
- PVC price reversal supports sentiment: PVC prices reversed from mid-January after China withdrew its 13% rebate policy, improving farmer and retailer sentiment; order run-rates from January are growing.
Krishna Rana: "So this is the area where we have entered and supplying additives and not the entire compound."
Pharma & Oleo: The Optionality Bets
Two early-stage ventures sit outside current revenue but carry meaningful medium-term optionality. Neither has committed capex yet; both follow an asset-light, prove-it-first approach.
- Pharma (Rivadu LifeSciences): A new subsidiary, 70% owned by Platinum and 30% by a scientist with multiple patents, will enter nutraceuticals, APIs, excipients, and niche pharma products. The go-to-market strategy is to hire third-party production capacity and sell into the market for two to three years before investing in own capex. Management is confident of generating good revenue in FY27 but declined to provide any figures.
- Oleo (Oleamides and derivatives): Currently in a CDMO process, getting products manufactured by third parties based on the company's own R&D. The plan is to conduct one year of seed marketing before committing to a 40,000-tonne capacity investment of ₹150–₹200 crores, funded through debt, internal accrual, or equity depending on circumstances at that time.
Margins: The Reset and the Recovery Path
EBITDA margins have structurally reset from 23% in FY23–FY24 to 15% currently, a function of product mix rather than operational deterioration. The recovery story rests on three levers: CPVC raw material optimisation, Egypt's structurally higher margins, and operating leverage as new capacity fills.
- The CPVC margin journey: CPVC contribution has climbed from 7% to 17% over the past year as the company scales, but optimal raw material cost has not yet been achieved. Further improvement is expected as procurement scales.
- India maintainable range: Management sees 15%–17% EBITDA as maintainable in India with the current product mix, translating to a PAT margin of 11%–12% for the entire portfolio.
- Egypt layers on top: With contribution margins 400–500 bps higher than India, Egypt's ramp-up should pull consolidated margins upward over the 2–3 year ramp period.
- PAT growth moderated in 9M: Despite strong revenue growth, PAT growth was moderated by higher depreciation from the Palghar expansion, lower other income, and higher COGS from the CPVC-heavy mix.
Capital Allocation & Promoter Moves
- Promoter share sale was debt-driven, not signal-driven: Approximately 5,30,000 shares (~1%) were sold in the market to repay personal loans. Management stated no further stake sale is planned in the short run.
- Balance sheet supports growth: The company carries low leverage and plans to fund organic expansion and potential inorganic moves from internal accrual and debt; an equity raise for the oleo business is possible but not decided.
- Acquisitions are on the radar but not urgent: Management might eye acquisitions as and when it wants to grow, but the major focus is on filling current capacity first.
Krishna Rana: "We had sold somewhere around 5,30,000 shares in the market because there were some personal loans which I had to get rid of."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | More than 40% growth | FY27 |
| Revenue CAGR | 35% CAGR | FY26 to FY29 |
| Egypt commercial production | Construction complete end-May, pre-commissioning June, production start 1st September; 100% plant running by December (exchange filing) | September–December 2026 |
| Calcium zinc lines | Full-scale commercial production | From April 2026 |
| Palghar capacity utilisation | 60,000 MT facility optimally utilised | By March/April 2026 |
| Egypt revenue | ₹250–₹300 crores | Over 3 years |
| Egypt EBITDA margin | 12%–13% initially, rising to 15%–16% | After first 2–3 years |
| India EBITDA margin | 15%–17% maintainable | Ongoing |
| Oleo capex | ₹150–₹200 crores for 40,000 tonnes capacity | After one year of seed marketing |
| Pharma capex | Own manufacturing investment | Post two to three years of asset-light market entry |
| Promoter stake | No further sale planned | Short run |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Standalone revenue | ₹102.62 cr, +31% YoY and +6% QoQ |
| Consolidated revenue | ₹104.67 cr, +12% YoY |
| 9M standalone revenue | ₹302.38 cr, +25% YoY |
| 9M consolidated revenue | ₹318.42 cr, +7.7% YoY |
| Gross margin | ~31%, vs 32.6% in Q3 FY25; higher CPVC mix |
| EBITDA | ₹16.25 cr, margin 15.8% |
| 9M EBITDA | ₹44.11 cr, margin 14.6% |
| Profit before tax | ₹17.54 cr, +15% YoY |
| Profit after tax | ₹12.93 cr, +18% YoY and +6.5% QoQ |
| EPS | ₹2.35 |
| 9M PAT | ₹37.58 cr |
| CPVC contribution margin | ~17% in Q3, up from ~12% in H1 and 7% last year |
| Lead-free products contribution margin | 30%–35% |
| Lead products contribution margin (India) | 18% |
| Palghar CPVC plant utilisation | 60%–65% of 12,000 tonnes capacity |
| Unit 1 flakes capacity utilisation | 95% |
| Powder capacity utilisation | 20%–30%, up from 10% previously |
| Promoter stake change | ~1% reduction, 5,30,000 shares sold for personal loan repayment |
| FY27 revenue growth target | >40% (ex-pharma) |
| FY26–FY29 revenue CAGR target | 35% (ex-pharma) |
| Egypt plant commercial production start | September 2026 target, with December 2026 final outlook |
| Egypt revenue potential (3 years) | ₹250–300 cr, ~50% utilisation of ₹600 cr total capacity |
| Egypt lead products contribution margin | 23%–24% |
| Egypt lead products EBITDA margin (initial) | 12%–13%, expected to rise to 15%–16% |
| India factories total revenue potential | ~₹1,400 cr (PVC: ₹700–750 cr, CPVC: ~₹600 cr) over 3–4 years |
| Portfolio PAT margin guidance | 11%–12% |
| India EBITDA margin maintainable range | 15%–17% with product mix |
| Net debt position | Net debt free |